Who are Sintrom's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Indion, PHYTONADIONE, Coumadin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/acenocoumarol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Sintrom — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sintrom (ACENOCOUMAROL) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: acenocoumarol. Area: Cardiovascular.

phase 3 acenocoumarol Vitamin K epoxide reductase complex subunit 1 Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Sintrom (ACENOCOUMAROL). Acenocoumarol works by blocking the enzyme that helps produce clotting factors in the liver.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Sintrom TARGET	ACENOCOUMAROL		phase 3	acenocoumarol	Vitamin K epoxide reductase complex subunit 1
Indion	PHENINDIONE	Sanofi	marketed	phenindione	Prothrombin, Vitamin K epoxide reductase complex subunit 1, Arachidonate 5-lipoxygenase	1982-01-01
PHYTONADIONE	PHYTONADIONE		marketed	Vitamin K [EPC]	Vitamin K epoxide reductase complex subunit 1 (VKORC1)	1982-01-01
Coumadin	warfarin	Generic (originally Wisconsin Alumni Research Foundation)	marketed	Vitamin K antagonist (anticoagulant)	Vitamin K epoxide reductase complex subunit 1-like protein 1, Cytochrome P450 2C9, Proprotein convertase subtilisin/kexin type 7	1954-01-01

Recent regulatory actions (last 90 days)

2026-03-13 — PHYTONADIONE · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (acenocoumarol class)

· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sintrom — Competitive Intelligence Brief. https://druglandscape.com/ci/acenocoumarol. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing